Fda is looking at this.
The Award for Excellence in Technology Transfer, presented by the Federal Laboratory Consortium for Technology Transfer, recognizes employees of its member laboratories and non-laboratory staff members who have accomplished outstanding work in the process of transferring federally developed technology to the commercial
marketplace. A panel of experts from industry, state and local government, academia, and the federal laboratory system judge the nominations.
nothing Cramer and co.has any knowledge of...of course.
Them street guys are routinely getting away with the most obvious tampering, and then they blame others.
nothing Cramer has any knowledge of...of course.
Them street guys are routinely getting away with the most obvious tampering, and they blame others.
can you tell who they work for?
- it s been here & done that before
State Street Corporation 5,012,236 4.25 24,860,690 Dec 31, 2013
BlackRock Institutional Trust Company, N.A. 3,514,797 2.98 17,433,393 Dec 31, 2013
Consonance Capital Management LP 2,986,946 2.53 14,815,252 Dec 31, 2013
BlackRock Fund Advisors 2,768,798 2.35 13,733,238 Dec 31, 2013
Vanguard Group, Inc. (The) 2,703,465 2.29 13,409,186 Dec 31, 2013
Northern Trust Corporation 1,395,110 1.18 6,919,745 Dec 31, 2013
TIAA-CREF Investment Management, LLC 613,348 0.52 3,042,206 Dec 31, 2013
Bridgeway Capital Management, Inc. 538,100 0.46 2,668,976 Dec 31, 2013
Bank of New York Mellon Corporation 526,058 0.45 2,609,247 Dec 31, 2013
UBS AG 502,339 0.43 2,491,601 Dec 31, 2013
Top Mutual Fund Holders
Holder Shares % Out Value* Reported
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF 5,578,860 4.73 13,947,150 Mar 31, 2014
iShares Russell 2000 Index Fund 1,744,620 1.48 4,361,550 Mar 31, 2014
Vanguard Total Stock Market Index Fund 1,562,768 1.33 7,751,329 Dec 31, 2013
Vanguard Extended Market Index Fund 850,675 0.72 4,219,348 Dec 31, 2013
TEMPE, Ariz., April 8, 2014 (GLOBE NEWSWIRE) -- Capstone Therapeutics (CAPS) ("the Company") and its joint venture affiliate, LipimetiX Development, LLC ("JV"), announced today the initiation of dosing for its AEM-28 (Apo E mimetic peptide) Phase 1 human clinical trial in LDL/non-HDL cholesterol reduction.
The clinical study is a Phase 1a randomized, placebo-controlled, double-blinded, single center dose escalation study. The primary objectives are to evaluate safety and tolerability and to determine preliminary pharmacokinetics/pharmacodynamics of AEM-28 in normal healthy volunteers with elevated cholesterol. Approximately 36 subjects are planned for treatment at a hospital-affiliated clinical site in Perth, Australia.
this is much more serious then Gale's malicious accusations.
INSY is sitting at over a billion market cap, with what many believe to be an inferior pain drug as its only driver...not only that INSY conducted alleged illegal marketing to even attain its current market penetration with its drug...
'The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business and operations. Specifically, Defendants made false and/or misleading statements concerning, and/or failed to disclose, among other things that: (i) the Company engaged in illegal and/or unethical marketing of Subsys; (ii) the Company was exposed to potential fines and other disciplinary actions as a result of its Subsys marketing practices; and, (iii) as a result, the Company's financial statements were materially false and misleading at all relevant times.'
The aforementioned class action law suit going on now against INSY, this seriously opens the door for
GALE to ramp up its marketing a grab a larger share of the market, in an ethical manner, with a more effective drug, that is easier to dose and easier for the consumer to consume...
Incys inhaler for pain meds verse abstral sublingual tablet.
What happens when all patients want tablet verse spray inhaler.
Who wants to wait for pain relief when galena offers less than 5 minutes
tablet you put under your tong , it disolves and 5-6 minutes patients pain is gone
plus I don't think patients really want to spray drugs in there lungs if they don't have too
Ask and you may get lucky.
Shares. Options. Never know.
Lawyers? A waist of time.
penile puerile ego manifestation.
All in concerted action with his buddies ambulance chasers.
insys drop from 55 to 37 is a concern for his bold boss.
Phase 3 target patient population defined: node positive, HLA A2/3,
HER2 IHC 1+/2+ or low to intermediate patients.
Phase 3 FDA approved SPA (Special Protocol Assessment)
established primary endpoint as 36 month DFS